Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $9.7 million.

  • Puma Biotechnology's Cash from Operations fell 1212.18% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year increase of 2736.78%. This contributed to the annual value of $38.9 million for FY2024, which is 4409.27% up from last year.
  • Per Puma Biotechnology's latest filing, its Cash from Operations stood at $9.7 million for Q3 2025, which was down 1212.18% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Cash from Operations ranged from a high of $17.3 million in Q3 2022 and a low of -$26.9 million during Q1 2022
  • For the 5-year period, Puma Biotechnology's Cash from Operations averaged around $5.2 million, with its median value being $9.7 million (2025).
  • Per our database at Business Quant, Puma Biotechnology's Cash from Operations tumbled by 1864864.86% in 2022 and then soared by 127176.24% in 2025.
  • Puma Biotechnology's Cash from Operations (Quarter) stood at -$5.4 million in 2021, then skyrocketed by 241.36% to $7.7 million in 2022, then surged by 36.08% to $10.5 million in 2023, then soared by 49.28% to $15.6 million in 2024, then tumbled by 37.85% to $9.7 million in 2025.
  • Its Cash from Operations was $9.7 million in Q3 2025, compared to $14.1 million in Q2 2025 and $3.6 million in Q1 2025.